Exelixis Inc: (NASD: EXEL)
$4.72
-0.10 (-2.08%)
Volume 1,047,176
Jun 19 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 4.71 - 4.84 |
| 52wk Low - High | 4.19 - 6.95 |
| Previous Close | 4.82 |
| Avg. Volume | 1,298,912 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 885.93 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.92 |
| P/E (F1) | 0.00 |
| Current Year Est. | -1.21 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
112 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -1.21 |
| Current Quarter Estimate | -0.29 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.92 |
| Expected Earnings Growth | NA |
Company Description
Exelixis Inc. is a leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.29 | -0.32 | -1.21 | -1.22 |
| Number of Estimates | 5 | 5 | 7 | 6 |
| Low Estimate | -0.31 | -0.38 | -1.26 | -1.35 |
| High Estimate | -0.26 | -0.30 | -1.14 | NA |
| Year Ago EPS | -0.24 | -0.20 | -0.86 | -1.21 |
| EPS Growth | -19.17% | -62.00% | -41.03% | -0.59% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| EXELIXIS INC | EXEL | 4.82 | |
|
| BIOGEN IDEC INC | BIIB | 210.80 | |
|
| MYRIAD GENETICS | MYGN | 26.44 | |
|
| PROTALIX BIOTHR | PLX | 5.08 | |
|
| ADDEX THERA LTD | ADDXF | 3.95 | |
|
| AETERNA ZENTARS | AEZS | 1.90 | |
|
| AFFYMAX INC | AFFY | 1.07 | |
|
| ALEXION PHARMA | ALXN | 92.39 | |
|
| ALNYLAM PHARMA | ALNY | 29.99 | |
|
| ANTHERA PHARMA | ANTH | 0.58 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -0.92 |
| Sales | 47 |
| Net Income | -166 |
| Price/Earnings | NA |
| Price/Book | 3.47 |
| Price/Cash Flow | NA |
| Price/Sales | 22.95 |
News
Myelofibrosis - Pipeline Review, H1 2013 - M2
Jun 19, 2013
Exelixis announces encouraging data from Phase II prostate cancer trial - Datamonitor
Jun 12, 2013
Exelixis announces encouraging data from thyroid cancer trials - Datamonitor
Jun 12, 2013
Exelixis initiates Phase III metastatic renal cell carcinoma trial - Datamonitor
Jun 12, 2013
Exelixis Announces Webcasts of Upcoming Investor Conference Presentations - Businesswire
Jun 5, 2013
Exelixis Begins Phase 3 Pivotal Trial of Cabozantinib in Patients With Metastatic Renal Cell Carcinoma - Close-Up Media
Jun 5, 2013
Exelixis Presents Cometriq Clinical Trial Data - Close-Up Media
Jun 5, 2013
Exelixis Presents Data from Docetaxel-Pretreated Patients - Close-Up Media
Jun 5, 2013
Broker Recommendations
| Current ABR | 2.00 |
| ABR (Last Week) | 2.00 |
| # of recs in ABR | 8 |
| Average Target Price | 5.88 |
| Industry Rank by ABR | 112 out of 265 |
| Rank in Industry | 29 out of 154 |
